The Conversation (0)
- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
Top Stocks
Top Resource Stocks
Top Tech Stocks
Top Life Science Stocks
Trending
Trending Articles
Trending Press Releases
Trending Companies
Trending Reports
Resource
Popular Lists
Investing Ideas
Outlook Reports
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
Investing Guides
Tech
Popular Lists
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
Investing Ideas
Outlook Reports
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
Investing Guides
Life Science
Popular Lists
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
Outlook Reports
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
Investing Guides
Nemaura Reports Third Quarter 2018 Financial Results
Feb. 12, 2019 08:54AM PST
Medical Device InvestingNemaura Medical (NASDAQ:NMRD) has announced its financial results for Q3 ended December 30, 2018. As quoted in the press release: Recent Highlights and Accomplishments: • Nemaura Signed License and Distribution Agreement for SugarBEAT® Commercial Launch in Qatar • Nemaura Successfully Completes Clinical Studies for SugarBEAT® FDA De-Novo 510(k) Submission • Nemaura Raised …
Nemaura Medical (NASDAQ:NMRD) has announced its financial results for Q3 ended December 30, 2018.
As quoted in the press release:
Recent Highlights and Accomplishments:
• Nemaura Signed License and Distribution Agreement for SugarBEAT® Commercial Launch in Qatar
• Nemaura Successfully Completes Clinical Studies for SugarBEAT® FDA De-Novo 510(k) Submission
• Nemaura Raised Circa $2M in Public Offering
• Nemaura Completed Key Stages of Technical File Review for SugarBEAT® CE Mark Approval
• Nemaura Announced Improvements to SugarBEAT® Warm Up Period
• Nemaura Announced Grant of U.S. Patent for SugarBEAT®
• Nemaura Announced Dr. Fred Schaebsdau to Lead Strategy and Business Development
Dr. Faz Chowdhury, CEO of Nemaura Medical, commented, “Over the past quarter, we have bolstered our financial position to better support the upcoming commercial launch of SugarBEAT® and filing of our FDA 510(k) submission.”
Latest News
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.